Prot. 7163-CL-3201: A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de novo Kidney Transplant Recipients

Project: Research project

StatusActive
Effective start/end date10/13/1710/13/20

Funding

  • Astellas Pharma Global Development, Inc. (Prot 7163-CL-3201)